• Vensica Medical

  Led · Equity · Oct 2017

  Vensica Medical is a urology therapeutics company developing a proprietary needle-free delivery system for Xeomin® (botulinum toxin A) aimed at treating overactive bladder (OAB). The company’s platform is intended to provide a minimally invasive, needle-less alternative for delivering botulinum toxin A. Vensica plans to use newly raised capital to accelerate upcoming Phase 2 clinical trials across the United States and Europe. As part of a strategic partnership with Merz, Vensica has secured exclusive rights to Xeomin® in needle-less therapeutic applications in several urologic indications and will receive Merz’s clinical development support. The company was established in the incubator program of The Trendlines Group and The Israel Innovation Authority and maintains an office in Herzliya, Israel. Leadership includes CEO Avner Geva and CTO Avi Eftel. Vensica is a clinical-stage biopharmaceutical company developing a proprietary ultrasound-assisted drug delivery platform for urological indications including overactive bladder, neurogenic bladder, and interstitial cystitis. The company has an exclusive arrangement with Merz Therapeutics to use Merz’s botulinum neurotoxin A (Xeomin®) for needle-free urological procedures. Vensica plans to use the new funding to conduct phase II multicenter clinical trials in Europe and the USA. It also intends to expand its workforce in Israel to support clinical and regulatory development of its device in collaboration with Merz. Vensica was founded in 2015 by Avner Geva and is based in Tel Aviv, Israel. The company is in the clinical development stage and is advancing its device and combination product toward later-stage trials. Vensica Medical is developing VensiCare, an ultrasound-based, needle-free drug-delivery system whose initial indication is delivery of botulinum toxin to treat overactive bladder (OAB). The company also holds intellectual property for delivering oncology agents to the bladder. Led by CEO Avner Geva, Vensica plans to commence human clinical trials of VensiCare for OAB in the fourth quarter of 2018. Vensica received a $2M investment from Cogentix Medical. Cogentix will take one seat on Vensica’s board and received options to acquire the entire company for an additional $8M. Cogentix is a global medical device company (NASDAQ: CGNT) focused on the Urology, Uro/Gyn and Gynecology markets.

No current team members are available.